Document:

EX-10.1

 Exhibit 10.1 

EMPLOYMENT AGREEMENT 
 THE
EMPLOYMENT AGREEMENT (as the same may be amended, restated, supplemented or otherwise modified from time to time hereafter, the “Agreement”) is effective as of December 19, 2016, and is entered into by and between Juniper
Pharmaceuticals, Inc., a Delaware corporation having its corporate offices at 33 Arch St, Suite 3110, Boston, MA, 02110 (the “Company”), and Jeffrey Young (“Executive”), 516 Central Avenue, Needham, MA, 02494. 

WHEREAS, the Company wishes to employ Executive on the terms and conditions set forth in the Agreement; and 

WHEREAS, the Company and Executive desire to enter into the Agreement so the rights, duties, benefits, and obligations of each regarding
Executive’s employment for and by the Company will be fully set forth under the terms and conditions stated within the Agreement; 

NOW THEREFORE, in consideration of the mutual promises and undertakings hereunder, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 
 1. Start Date, At-Will. 

Executives’ employment with the Company shall commence as on January 1, 2017, unless another date is mutually agreed upon by
Executive and the Company. For purposes of this Agreement, the actual first day of Executive’s employment with the Company shall be referred to as the “Start Date.” Executive’s employment is “at will.” Either the
Executive or the Company may terminate the Executive’s employment with the Company at any time for any or no reason, with or without notice. Nothing in the Agreement or in any other statement shall be interpreted to be in conflict with or to
eliminate or modify in any way the employment-at-will status of the Executive. 
 2. Title, Duties. 

(a) Executive shall be the Senior Vice President, Finance, Chief Financial Officer, Treasurer and Secretary of the Company. Executive will
perform duties customarily associated with such position, including, but not limited to, duties relating to the management of the financial affairs of the Company and its affiliates, investor relations matters, and such other duties commensurate
with the job description as may be assigned to Executive from time to time by the chief executive officer of the Company (the “Company CEO”). Executive shall have an office at the Company’s headquarters located in Boston,
Massachusetts. 
 (b) Executive agrees to devote his entire business time and attention to the performance of his duties under the
Agreement. Executive shall perform his duties for the Company to the best of his ability and shall use his best efforts to further the interests of the Company. Executive acknowledges he will be required to travel as reasonably necessary to perform
the services required of him under the Agreement. Executive represents and warrants to the Company that he is able to enter into the Agreement and that his ability to enter into the Agreement and to fully perform his duties hereunder are not limited
or restricted by any agreements or understandings between Executive and any other person. For the purposes of the Agreement, the term “person” means any natural person, corporation, partnership, limited liability partnership, limited
liability company, or any other entity of any nature. 
 (c) Executive will observe the rules, regulations, policies and/or procedures which
the Company may now or hereafter establish governing the conduct of its business, except to the extent that any such rules, regulations, policies and/or procedures may be inconsistent with the terms of the Agreement, in which case the terms of the
Agreement shall control. 

 3. Employment Contract. 

The Company and Executive acknowledge that the terms of his employment are set forth in the Agreement. If Executive’s employment
terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in the Agreement. 

4. Compensation. 
 Subject
to the terms and conditions of Paragraph 1 of the Agreement and Executive’s continued employment with the Company, and in consideration for the services to be provided hereunder by Executive, the Company hereby agrees to pay or otherwise
provide Executive with the following compensation during his employment with the Company: 
 (a) Subject to tax withholdings and other
legally required deductions, the Company shall pay Executive a sign on bonus of $45,000 as soon as practicable following the commencement of his employment with the Company. 

(b) Subject to tax withholdings and other legally required deductions, the Company will pay Executive an annual base compensation of $355,000
($14,791.67 semi-monthly) to be paid in accordance with the Company’s normal payroll practices (“Base Salary”). Executive acknowledges and understands that his position of employment with the Company is considered “exempt,”
as that term is defined under the Fair Labor Standards Act and applicable state or local law. As an exempt employee, Executive is not eligible to receive overtime pay. 

(c) In addition to Base Salary, and beginning in 2017, Executive shall be eligible to receive an annual performance bonus as the Board shall,
in its sole discretion, deem appropriate based upon the parameters and criteria contained in the Company’s bonus plan and in consultation with the Company’s CEO, and can range from 0% to 150% of targeted levels, depending on the degree of
attainment of pre-established Company goals for a particular year. Executive’s target bonus is equal to 45% of his Base Salary as then in effect. Executive’s performance bonus shall be based on the period from January 1 through
December 31 of each applicable calendar year. Except as provided in Section 7, to earn any performance bonus, Executive must be employed through the end of the year to which the bonus applies. The annual performance bonus if any, shall be
paid no later than March 15 following the end of each calendar year in which such bonus was earned. 
 (d) Executive shall also be
eligible in the sole discretion of the Board or the Compensation Committee of the Board (or any committee of the Board that shall replace such committee) to participate in the Company’s stock option plan as is from time to time in effect,
subject to the terms and conditions of such plan. The Executive shall receive on the Start Date (the “Grant Date”) an initial grant of 170,000 options to purchase shares of the Company’s common stock which options are to have a life
of seven years and vest at the rate of one-quarter on each of the first four anniversaries of the Grant Date. The purchase price per share shall be equal to the fair market value of the Company’s common stock, as determined by the closing price
on the Grant Date. Promptly after the Grant Date, the Company and Executive will execute and deliver to each other the Company’s then standard form of stock option agreement, evidencing the terms of the stock options. The Stock Options will be
subject to, and governed by, the terms and provisions of the stock option agreement. Executive must sign the stock option agreement to receive the stock option. 

(e) Additionally, upon program approval by the Board of Directors, if ever, Executive will be eligible to participate in the Company’s
Performance Share program. Under the program, the Company shall grant to Executive 25,000 performance-based RSUs (the “Performance 

  
 2 

 
Shares”). Performance Shares shall vest in accordance with pre-established criteria to be established by the Compensation Committee of the Company’s Board of Directors. Executive’s
eligibility to participate in the Performance Share program, if any, will be governed by the applicable performance share agreement required to be entered into between Executive and the Company. 

5. Benefits. 
 (a)
Executive and Executive’s eligible dependents shall be eligible for all employee benefit programs (including any 401(k), group life insurance, group medical, dental and vision, and short-term and long-term disability policies, plans and
programs) generally available to other executive level employees of the Company. 
 (b) Executive shall be entitled to accrue paid time off
(“PTO”) during the term of the Agreement in accordance with the Company’s standard policy and in an amount commensurate with other executive level employees of the Company. 

(c) Executive shall be entitled to reimbursement for all reasonable expenses that he incurs in connection with the performance of his duties
and obligations hereunder. Upon presentment by Executive of appropriate and sufficient documentation, as determined in the Company’s sole direction, the Company shall reimburse Executive for all such expenses in accordance with the
Company’s expense reimbursement policy, as in effect from time to time. 
 6. Termination Upon Death. 

Executive’s employment shall terminate immediately upon his death. 

7. Compensation Upon Termination. 

(a) Subject to Paragraphs 18 and 19 of the Agreement, if Executive’s employment is terminated by the Executive’s death or resignation
without Good Reason (as that term is defined below), or if Executive is terminated with or without Cause (as that term is defined below), Executive shall be entitled to receive (i) the Base Salary through the effective date of termination
together with any accrued but unused vacation pay and (ii) in the case of a termination by the Company without Cause, the Company shall pay to Executive (A) six (6) months of his final Base Salary; (B) an amount equal to six
(6) months of Executive’s target annual performance bonus in accordance with Paragraph 4(c), each of which shall be paid to him in installments beginning within sixty (60) days after the date of termination, subject to Paragraph 18
and (C) the amount equivalent to six (6) months of the Company’s portion of medical and dental benefits if these benefits were elected by Executive as of the date of termination. Such payments ((A) through (C)) shall be conditioned
upon execution and non-revocation by Executive of a separation agreement containing, among other terms, a release of claims with respect to the Company and its affiliates, entities and related persons and a nondisparagement provision, which the
Company shall present to Executive and which Executive shall sign no later than thirty (30) days after the date of termination. Except with respect to (B) above, Executive shall not be entitled to any annual performance bonus for the year
in which such termination occurs. 
 (b) For the purposes of Paragraph 7(a) above, “Cause” shall mean a good faith determination
by the Company that any of the following has occurred (i) any action or omission by the Executive involving the Executive’s fraud, embezzlement, or willful misconduct relating to his duties to the Company; (ii) the Executive’s
indictment or conviction for a criminal offense (other than a summary or similar offense) or a crime of moral turpitude; (iii) the Executive’s material breach of any of the provisions of the Agreement or obligations under any other written
agreement or covenant with or policy 

  
 3 

 
of the Company that results in a material injury to the Company; (iv) unauthorized use or disclosure by Executive of any confidential or proprietary information or trade secrets of the
Company or any other party to whom the Executive owes an obligation of nondisclosure as a result of his relationship with the Company that results in a material injury to the Company; or (v) Executive’s refusal to carry out the directives
of the Company CEO. 
 (c) Executive may terminate his employment hereunder with Good Reason, provided that Executive has first provided
written notice of such reason to the Company no later than thirty (30) days after the event or occurrence constituting Good Reason first arises, with such notice affording the Company thirty (30) days from the date of the Company’s
receipt of such notice to cure the deficiency, and further provided that, upon such cure by the Company, “Good Reason” shall not be deemed to exist for purposes of the Agreement. Subject to Paragraph 18, in the event Executive terminates
his employment with Good Reason, the Company shall pay to Executive (i) the Base Salary through the effective date of termination together with any accrued but unused vacation pay and (ii) (A) six (6) months of his final Base
Salary; (B) an amount equal to six (6) months of Executive’s target annual performance bonus amount in accordance with Paragraph 4(c), each of which shall be paid to him in installments beginning within sixty (60) days after the
date of termination, subject to Paragraph 18, and (C) the amount equivalent to six (6) months of the Company’s portion of medical and dental benefits if these benefits were elected by Executive as of the date of termination. Such
payments ((A) through (C)) shall be conditioned upon execution and non-revocation by Executive of a separation agreement containing, among other terms, a release of claims with respect to the Company and its affiliates, entities and related persons
and a nondisparagement provision, which the Company shall present to Executive and which Executive shall sign no later than thirty (30) days after the date of termination. Except with respect to (B) above, Executive shall not be entitled
to any annual performance bonus for the year in which such termination occurs. For the purposes of this Paragraph 7(c), “Good Reason” shall mean the occurrence of either of the following events without the consent of Executive: (a) a
material breach of the Agreement by the Company; or (b) a material reduction in Executive’s responsibility, authority, or duties relative to Executive’s responsibility, authority or duties as outlined in Paragraph 2 above. 

(d) If Executive is terminated without Cause or resigns with Good Reason within twenty four (24) months after a Change of Control as
defined below, the Company shall pay to Executive: (i) the Base Salary through the effective date of termination together with any accrued but unused vacation pay and (ii) a lump sum payment equal to (A) twelve (12) months of his
final Base Salary (B) an amount equal to twelve (12) months of Executive’s target annual performance bonus in accordance with Paragraph 4(c); and (C) an amount equal to twelve (12) months of the Company’s portion of
medical and dental benefits if these benefits were elected by Executive as of the date of termination, which lump sum payment ((A through C)) shall be paid to him within sixty (60) days after the date of termination, subject to Paragraphs 18
and 19 of the Agreement. Executive shall fully vest in all equity granted under Paragraphs 4(c) and 4(d). Such lump sum payment ((A) through (C)) shall be conditioned upon execution and non-revocation by Executive of a separation agreement
containing, among other terms, a release of claims with respect to the Company and its affiliates, entities and related persons and a nondisparagement provision, which the Company shall present to Executive and which Executive shall sign no later
than thirty (30) days after the date of termination. 
 (e) For the purposes of Paragraph 7(d) above, a “Change of Control”
shall occur if an entity, or a group of entities acting together, acquires control of 50% or more of the Company’s voting securities with the power to elect a majority of the Board. 

8. Restrictive Covenants. 

The Executive and Company agree that the Company is engaged in a highly competitive industry and would suffer irreparable harm and incur
substantial damage if Executive were to enter into competition with the Company. Therefore, in order for the Company to protect its legitimate business interests, Executive covenants and agrees as follows: 

  
 4 

 (a) Executive shall not, at any time during his employment with the Company and for a period of
twelve (12) months thereafter, anywhere in United States, either directly or indirectly: (i) accept employment with or render services to any person or entity that is a business competitor of the Company, or has at any time during
Executive’s employment with the Company engaged or attempted to engage in business competition with the Company, in a position, capacity, or function that is similar, in title or substance, whether in whole or in part, to any position,
capacity, or function that Executive held with or in which Executive served the Company; or (ii) invest in any person or entity that is a business competitor of the Company, or has at any time during Executive’s employment with the Company
engaged or attempted to engage in business competition with the Company, except that Executive may own up to five percent (5%) of any outstanding class of securities of any company registered under Section 12 of the Securities Exchange Act
of 1934, as amended; 
 (b) Executive shall not, at any time during his employment with the Company and for a period of twelve
(12) months thereafter, for any reason, on his own behalf or on behalf of any other person or entity: (i) solicit, invite, induce, cause, or encourage to alter or terminate his, her, or its business relationship with the Company, any
client, customer, supplier, vendor, licensee, licensor, or other person or entity that, at any time during Executive’s employment with the Company, had a business relationship with the Company, or any person or entity whose business the Company
was soliciting or attempting to solicit at the time of Executive’s termination and (a) with whom Executive had contact, or for whom Executive performed services, to any extent, during his employment with the Company, and (b) with whom
Executive did not have a business relationship prior to his employment with the Company; (ii) solicit, entice, attempt to solicit or entice, or accept business from any such client, customer, supplier, vendor, licensee, licensor, person, or
entity; or (iii) interfere or attempt to interfere with any aspect of the business relationship between the Company and any such client, customer, supplier, vendor, licensee, licensor, person, or entity; and 

(c) Executive shall not, at any time during his employment with the Company and for a period of twelve (12) months thereafter, either
directly or indirectly, on his own behalf or on behalf of any other person or entity: (i) solicit, invite, induce, cause, or encourage any director, officer, employee, agent, representative, consultant, or contractor of the Company to alter or
terminate his, his, or its employment, relationship, or affiliation with the Company; (ii) interfere or attempt to interfere with any aspect of the relationship between the Company and any such director, officer, employee, agent,
representative, consultant, or contractor; or (iii) engage, hire, or employ, or cause to be engaged, hired, or employed, in any capacity whatsoever, any such director, officer, employee, agent, representative, consultant, or contractor. 

(d) Executive represents, warrants, agrees, and understands that: (i) the covenants and agreements set forth in the Paragraph 8 of the
Agreement are reasonable in their geographic scope, temporal duration, and content; (ii) the Company’s agreement to employ Executive, and a portion of the compensation to be paid to Executive hereunder, are in consideration for such
covenants and Executive’s continued compliance therewith; (iii) Executive shall not raise any issue of, nor contest or dispute, the reasonableness of the geographic scope, temporal duration, or content of such covenants and agreements in
any proceeding to enforce such covenants and agreements; (iv) the enforcement of any remedy under the Agreement will not prevent Executive from earning a livelihood, because Executive’s past work history and abilities are such that
Executive can reasonably expect to find work in other areas and lines of business; (v) the covenants and agreements set forth in the Paragraph 8 of the Agreement are essential for the Company’s reasonable protection, are designed to
protect the Company’s legitimate business interests, and are necessary and implemented for legitimate business reasons; and (vi) in entering into the 

  
 5 

 
Agreement, the Company has relied upon Executive’s representation that he will comply in full with the covenants and agreements set forth in the Paragraph 8 of the Agreement. The
post-employment restricted periods under this Paragraph 8 shall be extended by each day that the Executive is in breach of this Section. 

9. Confidentiality. 
 The
Employee Proprietary Information and Inventions Agreement to be executed on the date hereof, between the Company and Executive, is attached hereto as Exhibit A and incorporated by reference as if fully set forth herein, 

10. Indemnification. 
 The
Indemnification Agreement to be executed on the date hereof, between the Company and Executive, is attached hereto as Exhibit B and incorporated by reference as if fully set forth herein. 

11. Cooperation. 
 (a)
Executive agrees to cooperate on a reasonable basis in the truthful and honest prosecution and/or defense of any claim in which the Company, its affiliates, and/or its subsidiaries may have an interest (subject to reasonable limitations concerning
time and place), which may include without limitation making himself available on a mutually agreed, reasonable basis to participate in any proceeding involving the Company, its affiliates, and/or its subsidiaries, allowing himself to be interviewed
by representatives of the Company, its affiliates, and/or its subsidiaries without asserting or claiming any privilege against the Company, its affiliates, and/or its subsidiaries, appearing for depositions and testimony without requiring a subpoena
and without asserting or claiming any privilege against the Company, its affiliates, and/or its subsidiaries, and producing and/or providing any documents or names of other persons with relevant information without asserting or claiming any
privilege against the Company, its affiliates, and/or its subsidiaries; provided that, if such services are required after termination of the Agreement, the Company, its affiliates, and/or its subsidiaries shall provide Executive with reasonable
compensation for the time actually expended in such endeavors and shall pay his reasonable expenses incurred at the prior and specific request of the Company, its affiliates, and/or its subsidiaries. 

(b) Nothing in the provision shall be construed or applied so as to obligate Executive to violate the law or any legal obligation. Further,
nothing in the Agreement shall be construed as, or shall interfere with, abridge, limit, restrain, or restrict Executive’s right to communicate with any federal, state, or local government agency charged with the enforcement and/or
investigation of claims of discrimination, harassment, retaliation, improper wage payments, or any other unlawful employment practices under federal, state, or local law, or to file a charge, claim, or complaint with, or participate in or cooperate
with any investigation or proceeding conducted by, any such agency. 
 12. Remedies. 

Executive acknowledges and agrees that the Company’s remedy at law for a breach or threatened breach of the provisions of the Agreement
would be inadequate and, in recognition of the fact, in the event of a breach or threatened breach by Executive of any provision of the Agreement, it is agreed that, in addition to any available remedy at law, the Company shall be entitled to,
without posting any bond, specific performance, a temporary restraining order, a temporary or permanent injunction, or any other equitable relief or remedy which may then be available; provided, however, nothing herein shall be deemed to relieve the
Company of its burden to prove grounds warranting such relief nor preclude Executive from contesting such grounds or facts in support thereof. Nothing herein contained shall be construed as prohibiting the Company from pursuing any other remedies
available to it for such breach or threatened breach thereof. 

  
 6 

 13. Applicable Laws and Consent to Jurisdiction. 

The validity, construction, interpretation, and enforceability of the Agreement shall be determined and governed by the laws of the
Commonwealth of Massachusetts without giving effect to the principles of conflicts of law. For the purpose of litigating any dispute that arises under the Agreement, the parties hereby consent to exclusive jurisdiction of, and agree that such
litigation shall be conducted in, any state or federal court located in the Commonwealth of Massachusetts. 
 14. Severability. 

The provisions of the Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in
whole or in part, the remaining provisions shall nevertheless be binding and enforceable. The parties agree that the covenants set forth herein are reasonable. Without limiting the foregoing, it is the intent of the parties that the covenants set
forth herein be enforced to the maximum degree permitted by applicable law. As such, the parties ask that if any court of competent jurisdiction were to consider any provisions of the Agreement to be overly broad based on the circumstances at the
time enforcement is requested, that such court “blue pencil” the provision and enforce the provision to the full extent that such court deems it to be reasonable in scope. 

15. Miscellaneous, Waiver. 

Executive further agrees that the Agreement, together with the Exhibits incorporated by reference as if fully set forth herein, sets forth the
entire employment agreement between the Company and Executive, supersedes any and all prior agreements between the Company and Executive, and shall not be amended or added to accept in a writing signed by the Company and Executive. Neither e-mail
correspondence, text messages, nor any other electronic communications constitutes a writing for purposes of the Paragraph 15. Executive understands that he may not assign his duties and obligations under the Agreement to any other party and that
the Company may, at any time and without further action or the consent of the Executive, assign the Agreement to any of its affiliated companies. In entering into and performing under the Agreement, neither the Company nor Executive has relied upon
any promises, representations, nor statements except as expressly set forth herein. 
 16. Counterparts. 

The Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together shall
constitute one and the same agreement. 
 17. Successors and Assigns. 

The Agreement shall be binding on the successors and heirs of Executive and shall inure to the benefit of the successors and assigns of the
Company. 
 18. Compliance with Section 409A of the Internal Revenue Code of 1986, as Amended (Section 409A). 

(a) Notwithstanding anything herein to the contrary, to the maximum extent permitted by applicable law, amounts payable to Executive pursuant
to Paragraph 7 of the Agreement 

  
 7 

 
shall be made in reliance upon Treas. Reg. Section 1.409A-1 (b)(9) (Separation Pay Plans) or Treas. Reg. Section 1.409A-1(b)(4) (Short-Term Deferrals), as applicable. For the purpose,
each payment (including each monthly installment) shall be considered a separate and distinct payment, and each payment made in reliance on Treas. Reg. Section 1.409A-1(b)(9) shall only be payable if the Executive’s termination of
employment constitutes a “separation from service” within the meaning of Treas. Reg. Section 1.409A-1(h). 
 (b)
Notwithstanding anything contained in the Agreement to the contrary, no amount payable on account of Executive’s termination of employment which constitutes a “deferral of compensation” (“Section 409A Deferred Compensation”)
within the meaning of the Treasury Regulations issued pursuant to Section 409A of the Code (the “Section 409A Regulations”) shall be paid unless and until Executive has incurred a “separation from service”, and if the 60-day
payment period set forth under Paragraphs 7(a) or 7(d) of the Agreement commences in one taxable year and ends in another, then payment under such paragraphs shall not be made until the second taxable year. For purposes of the Agreement,
“separation from service” shall have the meaning of such term as defined by the Section 409A Regulations, and each payment shall be considered a separate and distinct payment. Furthermore, if Executive is a “specified
employee” within the meaning of the Section 409A Regulations as of the date of Executive’s separation from service, no amount that constitutes Section 409A Deferred Compensation which is payable on account of Executive’s
separation from service shall be paid to Executive before the date (the “Delayed Payment Date”) which is first business day of the seventh month after the date of Executive’s separation from service or, if earlier, the date of
Executive’s death following such separation from service. All such amounts that would, but for the Paragraph, become payable prior to the Delayed Payment Date will be accumulated and paid on the Delayed Payment Date. 

(c) To the extent that all or any portion of the Company’s payment of benefits or reimbursements or in-kind benefits provided to
Executive (the “Company-Provided Benefits”) would constitute Section 409A Deferred Compensation, then, for the duration of the applicable period during which the Company is required to provide such benefits: (a) the amount of
Company-Provided Benefits furnished in any taxable year of Executive shall not affect the amount of Company-Provided Benefits furnished in any other taxable year of Executive; (b) any right of Executive to Company-Provided Benefits shall not be
subject to liquidation or exchange for another benefit; and (c) any reimbursement for Company-Provided Benefits to which Executive is entitled shall be paid no later than the last day of Executive’s taxable year following the taxable year
in which Executive’s expense for such Company-Provided Benefits was incurred. 
 (d) The Company intends that income provided to
Executive pursuant to the Agreement will not be subject to taxation under Section 409A of the Code. The provisions of the Agreement shall be interpreted and construed in favor of satisfying any applicable requirements of Section 409A and
the Section 409A Regulations. However, the Company does not guarantee any particular tax effect for income provided to Executive pursuant to the Agreement. In any event, except for the Company’s responsibility to withhold applicable income
and employment taxes from compensation paid or provided to Executive, the Company shall not be responsible for the payment of any applicable taxes incurred by Executive on compensation paid or provided to Executive pursuant to the Agreement. 

19. Limitation on Payments. 

(a) In the event that the post-termination payments and other benefits provided for in the Agreement or otherwise payable to Executive
(i) constitute “parachute payments” within the meaning of Section 280G of the Code and (ii) but for the Paragraph 19, would be subject to the excise tax imposed by Section 4999 of the Code, then Executive’s
post-termination payments benefits will be either: (a) delivered in full, or delivered as to such lesser extent which would result in no portion of such post-

  
 8 

 
termination payments or other post-termination benefits being subject to the excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable
federal, state and local income taxes and the excise tax imposed by Section 4999 of the Code, results in the receipt by Executive on an after-tax basis, of the greatest amount of post-termination payments or benefits, notwithstanding that all
or some portion of such post-termination payments or benefits may be taxable under Section 4999 of the Code. If a reduction in the severance and other benefits constituting “parachute payments” is necessary so that no portion of such
post-termination payments or benefits is subject to the excise tax under Section 4999 of the Code, the reduction shall occur in the following order: (i) reduction of the post-termination payments under Paragraph 7; (ii) reduction of
other cash payments, if any; (iii) cancellation of accelerated vesting of equity awards; and (iv) reduction of continued employee benefits. In the event that acceleration of vesting of equity award compensation is to be reduced, such
acceleration of vesting shall be cancelled in the reverse order of the date of grant of Executive’s equity awards. If two or more equity awards are granted on the same date, each award will be reduced on a pro-rata basis. In no event shall the
Executive have any discretion with respect to the ordering of payment reductions. 
 (b) Unless the Company and Executive otherwise agree in
writing, any determination required under the Paragraph 19 will be made in writing by an independent firm immediately prior to Change of Control (the “Firm”), whose determination will be conclusive and binding upon Executive and the
Company. For purposes of making the calculations required by the Paragraph 19, the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application
of Sections 280G and 4999 of the Code. The Company and Executive will furnish to the Firm such information and documents as the Firm may reasonably request in order to make a determination. The Company will bear all costs the Firm may reasonably
incur in connection with any calculations contemplated by the Paragraph 19. 
 20. Notices. 

Any notice required or permitted hereunder shall be in writing and shall be sufficiently given if personally delivered or if sent by registered
or certified mail, postage prepaid, with return receipt requested, addressed: (a) in the case of the Company, to Juniper Pharmaceuticals, Inc., 33 Arch Street, 31st floor, Boston, MA, 02109,
attn.: Company CEO, and (b) in the case of Executive, to Executive’s last known address as reflected in the Company’s records, or to such other address as Executive shall designate by written notice to the Company. Any notice given
hereunder shall be deemed given at the time of receipt thereof by the person to whom such notice is given. 
 IN WITNESS WHEREOF, the
parties have executed the Agreement as of the dates set forth below. 
  

					
	EXECUTIVE	 		 	Juniper Pharmaceuticals, Inc.
			
	/s/ Jeffrey Young	 		 	/s/ Alicia Secor
	Jeffrey Young	 		 	Alicia Secor
		 		 	President and Chief Executive Officer
			
	Date: December 19, 2016	 		 	Date: December 19, 2016

  
 9 

 Exhibit A 

EMPLOYEE PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT 

The Employee Proprietary Information and Inventions Agreement (the “Agreement”) is made as of December 19, 2016,
between Jeffrey Young (referred to below as “I”, “My”, “Myself”, or “Me”) and Juniper Pharmaceuticals, Inc., having an office at 33 Arch Street, Suite 3110, Boston, MA, 02110 (referred to below
together with its subsidiaries and affiliates as the “Company”). 
 RECITALS 

A. The Company is engaged in a continuous program of research, development, production, distribution, and marketing with respect to its
present and future business; and 
 B. I understand that My employment with the Company creates a relationship of confidence and trust
between the Company and Me with respect to any information: (a) applicable to the business of the Company, or (b) applicable to the business of any client or customer of the Company, that may be made known to Me by the Company, any client
or customer of the Company, or learned by Me during the period of My employment. I understand that this information constitutes a very valuable asset of the Company. 

NOW, THEREFORE, in consideration of My employment by the Company and the salary and other employee benefits I will receive from the Company
for My service, which in all cases are subject to Section 12(a) of the Agreement, I hereby agree as follows: 
 1. Proprietary
Information. The Company possesses and will come to possess information that has been created, discovered or developed, or has otherwise become known to the Company (including without limitation, information created, discovered, developed or
made known by or to Me arising out of My employment by the Company), and/or in which property rights have been assigned or otherwise conveyed to the Company, which information has commercial value in the business in which the Company is engaged. All
of the aforementioned information is “Proprietary Information.” Any information disclosed to Me or to which I have access (whether I or others originated it) during the time I am employed by the Company, that the Company or I reasonably
consider Proprietary Information or that the Company treats as Proprietary Information is Proprietary Information. 
 By way of
illustration, but not limitation, Proprietary Information includes trade secrets, processes, formulae, data and know-how, improvements, inventions, techniques, marketing plans, strategies, forecasts, customer lists, and finance and business systems.

 (a) Company as Sole Owner. I agree and acknowledge that all Proprietary Information, and all Inventions (defined below in
Section 4(a) of the Agreement), shall be the sole property of the Company and its assigns, and the Company and its assigns shall be the sole owner of all patents and trade secrets and any other rights in connection therewith. 

(b) Assignment of Rights; Obligation of Confidentiality. I hereby assign to the Company any rights I may have or acquire in all
Proprietary Information. At all times during My employment by the Company and at all times after termination of such employment, I will keep in confidence and trust all Proprietary Information and, except as I may be authorized to make disclosure in
the ordinary course of performing My duties as an employee of the Company, I will not disclose, sell, use, lecture upon or publish any Proprietary Information or anything relating to it without the prior written consent of the Company. 

 2. Retention of Rights. Notwithstanding any other provision hereof, nothing in the
Agreement shall be construed as, or shall interfere with, abridge, limit, restrain, or restrict My right: (i) to engage in any activity or conduct protected by Section 6 or any other provision of the National Labor Relations Act; or
(ii) to communicate with any federal, state, or local government agency charged with the enforcement and/or investigation of claims of discrimination, harassment, retaliation, improper wage payments, or any other unlawful employment practices
under federal, state, or local law, or to file a charge, claim, or complaint with, or participate in or cooperate with any investigation or proceeding conducted by, any such agency. 

3. Other Proprietary Rights. All documents, data, records, apparatus, equipment, chemicals, molecules, organisms, and other physical
property, whether or not pertaining to Proprietary Information, furnished to Me by the Company or produced by Me or others in connection with My employment shall be and remain the sole property of the Company and shall be returned promptly to the
Company as and when requested by the Company. Should the Company not so request, I shall return and deliver all such property upon termination of My employment by Me or the Company for any reason and I will not take with Me any such property or any
reproduction of such property upon such termination. 
 4. Obligations Regarding Inventions. 

(a) I will promptly disclose to the Company, or any persons designated by it, and will not use Myself or disclose to anyone else at any time
during or after My employment without the prior written consent of the Company, all improvements, inventions, formulae, processes, techniques, know-how and data (whether or not they can be patented, trademarked or copyrighted), made, conceived,
reduced to practice or learned by Me, either alone or jointly with others, during the period of My employment, which are related to or useful in the business of the Company, or which the Company would be interested in, or result from tasks assigned
to Me by the Company, or result from use of any premises owned, leased or contracted for by the Company (all said improvements, inventions, formulae, processes, techniques, know-how, and data initiated or developed during My employment shall be
collectively hereinafter called “Inventions”); such disclosure shall continue after termination of My employment with the Company with respect to any Invention, which in all cases are subject to Section 4(c) of the Agreement. 

(b) Company Sole Owner of Patent Rights. I will promptly and fully disclose the existence and describe the nature of any such Invention
to the Company in writing and without request. I agree that all Inventions shall be the sole property of the Company and its assigns, and the Company and its assigns shall be the sole owner of all patents, copyrights, trade secrets, and other
intellectual property rights (collectively, “Patent Rights”) in connection therewith. I will, with respect to any such Invention, keep current, accurate and complete records that will belong to the Company and will be kept stored on the
Company premises while I am employed by the Company and shall be turned over to the Company immediately upon termination of My employment. 

(c) Assignment of Inventions and Patent Rights; Duty to Cooperate. I hereby assign to the Company any rights I may have or acquire in
all Inventions. I further agree as to all Inventions and Proprietary Information to assist the Company in every proper way (but at the Company’s expense) to obtain and from time to time enforce Patent Rights regarding the Inventions or
Proprietary Information in any and all countries, and to that end I will execute all documents for use in applying for and obtaining such patents or copyrights thereon and enforcing same, as the Company may desire, together with any assignments
thereof to the Company or entities or persons designated by it. I agree further that these obligations to assist the Company in obtaining and enforcing Patent Rights in any and all countries shall continue beyond the termination of My employment, in
return for which assistance after termination the Company shall compensate Me at a reasonable rate for time actually spent by Me at the Company’s request on such assistance. 

  
 -A-2- 

 6. Prior Inventions List. [Please initial one of the following two entries.] 

        As a matter of record, I have attached hereto a complete list of all inventions or improvements
relevant to the subject matter of My employment by the Company which have been made or conceived or first reduced to practice by Me alone or jointly with others prior to My employment by the Company which I desire to remove from the operation of the
Agreement; and I warrant that such list is complete. 
 X    No such list is attached to the Agreement, and I represent that I
have made no such inventions or improvements prior to or My employment by the Company. 
 7. No Breach of Confidentiality. I
represent that My performance of all terms of the Agreement and that My employment by the Company does not and will not breach any obligation of confidentiality that I have to others, which existed prior to My employment by the Company. I have not
brought or used, and will not bring with Me to the Company or use any equipment, supplies, facility or trade secret information of any former employer or any other person, which information is not generally available to the public, unless I have
obtained written authorization for their possession and use, and promptly provided such written authorization to the Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with the
Agreement. 
 8. Injunctive Relief. I acknowledge and agree that the Company’s remedy at law for a breach or threatened breach
of any of the provisions of the Agreement would be inadequate and, in recognition of that fact, in the event of any such breach or threatened breach, I agree that, in addition to its remedy at law, the Company shall be entitled to equitable relief
in the form of specific performance, a temporary restraining order, a temporary or permanent injunction or any other equitable remedy that may then be available. Nothing herein contained shall be construed as prohibiting the Company from pursuing
any other remedies available to it for such breach or threatened breach. 
 9. Not Debarred. I warrant and represent that I have
never been, and am not currently an individual who has been, debarred by the United States Food and Drug Administration (“FDA”) pursuant to 21 U.S.C. §335a (a) or (b) (“Debarred Individual”) from providing services
in any capacity to a person that has an approved or pending drug product application. I further warrant and represent that I have no knowledge of any FDA investigations of, or debarment proceedings against, Me or any person or entity with which I
am, or have been, associated, and I will immediately notify the Company if I become aware of any such investigations or proceedings during the term of My employment with the Company. 

10. Protected Disclosures. I understand that nothing contained in this Agreement limits my ability to communicate with any federal,
state or local governmental agency or commission, including to provide documents or other information, without notice to the Company. I also understand that nothing in this Agreement limits my ability to share compensation information concerning
myself or others, except that this does not permit me to disclose compensation information concerning others that I obtain because my job responsibilities require or allow access to such information. 

11. Defend Trade Secrets Act of 2016. I understand that pursuant to the federal Defend Trade Secrets Act of 2016, I shall not be
held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to
an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. 

  
 -A-3- 

 12. Miscellaneous Provisions. 

(a) Employment. Nothing in the Agreement shall alter My “at will” employee status or be construed to create a specific term
of employment or a promise of continued employment. Either I or the Company may terminate the employment relationship for any reason at any time, with or without notice. 

(b) Enforceability. If one or more of the provisions contained in the Agreement shall, for any reason, be held to be excessively broad
as to scope, activity, subject or otherwise, so as to be unenforceable at law, such provision or provisions shall be construed by the appropriate judicial body by limiting or reducing it or them, so as to be enforceable to the maximum extent
compatible with then applicable law. If any provision of the Agreement shall be declared invalid, illegal or unenforceable, such provision shall be severed and all remaining provisions shall continue in full force and effect. 

(c) Assignment. The Agreement is not assignable by Me without the written consent of the Company, which consent may be withheld for any
reason or no reason. In light of the very personal and critical nature of the Agreement, I recognize that it is unlikely such consent would ever be granted. The Company may assign or otherwise transfer this Agreement to any person or entity. 

(d) Entire Agreement. The Agreement contains the entire agreement between Me and the Company with respect to the subject matter of the
Agreement. The Agreement may be amended only by a written instrument signed by Me and the Company. 
 (e) Binding Effect. The
Agreement shall be binding upon Me, My heirs, executors, assigns and administrators and shall inure to the benefit of the Company, its successors and assigns. 

(f) Governing Law. The Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts
without regard to its rules on conflicts of law. 

  
 -A-4- 

 Exhibit B 

INDEMNIFICATION AGREEMENT 

The Agreement (“Agreement”) is made and entered into as of the 19th day of December, 2016, by and between Juniper Pharmaceuticals,
Inc., a Delaware corporation (the “Corporation”) and Jeffrey Young (“Indemnitee”). 
 WHEREAS the Board of Directors
(the “Board”) has determined that the best interests of the Corporation require that persons serving as directors of, and in other capacities for, the Corporation receive better protection from the risk of claims and actions against them
arising out of their service to and activities on behalf of the Corporation; and 
 WHEREAS, the Agreement is a supplement to and in
furtherance of Article VI of the amended and restated by-laws of the Corporation, any rights granted by the Certification of Incorporation of the Corporation and any resolutions adopted pursuant thereto and shall not be deemed to be a substitute
therefore nor to diminish or abrogate any rights of the Indemnitee thereunder; and 
 WHEREAS, Indemnitee is willing to serve, continue to
serve and take on additional service for or on behalf of the Corporation on the condition that Indemnitee be indemnified according to the terms of the Agreement; 

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Corporation and Indemnitee do hereby covenant and
agree as follows: 
 Section 1. Definitions. 

For purposes of the Agreement: 

(a) “Change in Control” shall be deemed to have occurred if (a) there shall have consummated (i) any consolidation or
merger of Corporation in which Corporation is not the continuing or surviving entity or pursuant to which shares of Corporation’s common stock would be converted to cash, securities or other property, other than a merger of Corporation in which
the holders of Corporation’s common stock immediately prior to the merger have the same proportionate ownership of common stock of the surviving entity immediately after the merger, or (ii) any sale, lease, exchange or transfer (in one
transaction or a series of related transactions) of all, or substantially all, of the assets of the Corporation; or (b) the stockholders of the Corporation approve a plan or proposal for the liquidation or dissolution of the Corporation; or
(c) any person (as that term is used in Sections 13(d) and 14(d)(z) of the Securities and Exchange Act, as amended (the “Exchange Act”)) shall become a beneficial owner (within the meaning of Rule 13d-2 under the Exchange Act) of 40%
or more of Corporation’s outstanding common stock; or (d) during any period of two consecutive years, individuals who at the beginning of such period constitute the entire Board shall cease for any reason to constitute a majority thereof
unless the election, or the nomination for election by Corporation’s stockholders, of each new director was approved by a vote of at least 50% of the directors eligible to vote who were directors at the beginning of the period. 

(b) “Disinterested Director” means a director of the Corporation who is not and was not a party to the Proceeding in respect of which
indemnification is sought by Indemnitee. 
 (c) “Effective Date” means the date first written above. 

 (d) “Expenses” mean all reasonable attorneys’ fees, retainers, court costs,
transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements and expenses of the type customarily incurred in
connection with prosecuting, defending, preparing to prosecute or defend, investigating, or being or preparing to be a witness in a Proceeding. 

(e) “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither
presently is, nor in the past five years has been, retained to represent: (i) the Corporation or Indemnitee in any other matter material to either such party, or (ii) any other party to the Proceeding giving rise to a claim for
indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in
representing either the Corporation or Indemnitee in an action to determine Indemnitee’s rights under the Agreement. 
 (f)
“Proceeding” means an action, suit, arbitration, alternate dispute resolution mechanism, investigation, administrative hearing or any other proceeding, whether civil, criminal, administrative or investigative, except one initiated by an
Indemnitee pursuant to Section 11 of the Agreement to enforce Indemnitee’s rights under the Agreement. 
 Section 2. Service by
Indemnitee. 
 Indemnitee agrees to serve as an officer or director of the Corporation, and, at its request, as a director, officer,
employee, agent or fiduciary of certain other corporations and entities. 
 Indemnitee may at any time and for any reason resign from any
such position (subject to any other contractual obligation or any obligation imposed by operation of law). 
 Section 3. Indemnification - General.

 The Corporation shall indemnify, and advance Expenses to, Indemnitee as provided in the Agreement to the fullest extent permitted by
applicable law in effect on the date hereof and to such greater extent as applicable law may thereafter from time to time permit. The rights of Indemnitee provided under the preceding sentence shall include, but shall not be limited to, the rights
set forth in the other Sections of the Agreement. 
 Section 4. Proceeding Other Than Proceedings by or in the Right of the Corporation. 

Indemnitee shall be entitled to the rights of indemnification provided in the Section if, by reason of Indemnitee’s employment or service
as an officer or director, Indemnitee is, or is threatened to be made, a party to any threatened, pending or completed Proceeding, other than a Proceeding brought by or in the right of the Corporation to procure a judgment in its favor. 

Pursuant to the Section, Indemnitee shall be indemnified against Expenses, judgments, penalties, fines and amounts paid in settlement,
actually and reasonable incurred by Indemnitee or on Indemnitee’s behalf in connection with any such Proceeding if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of
the Corporation, and, with respect to any criminal Proceeding, had no reasonable cause to believe Indemnitee’s conduct was unlawful. 

  
 -B 2- 

 Section 5. Proceedings by or in the Right of the Corporation. 

Indemnitee shall be entitled to the rights of indemnification provided in the Section if, by reason of his status as an employee or director of
the Corporation, Indemnitee is, or is threatened to be made, a party to any threatened, pending or completed Proceeding brought by or in the right of the Corporation to procure a judgment in its favor. Pursuant to the Section, Indemnitee shall be
indemnified against Expenses, judgments, penalties, fines and amounts paid in settlement, actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with any such Proceeding if Indemnitee acted in good faith and in a
manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation. 
 Notwithstanding the foregoing, no indemnification
against such Expenses shall be made in respect of any claim, issue or matter in any such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Corporation if applicable law prohibits such indemnification unless the Court of
Chancery of the State of Delaware, or the court in which such Proceeding shall have been brought or is pending, shall determine that indemnification against Expenses may nevertheless be made by the Corporation. 

Section 6. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. 

Notwithstanding any other provision of the Agreement, to the extent that Indemnitee is, by reason of Indemnitee’s employment or service as
an officer or director, a party to and is successful, on the merits or otherwise, in any Proceeding, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection
therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Corporation shall indemnify Indemnitee against
all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with each successfully resolved claim, issue or matter. For the purposes of the Section and without limiting the foregoing, the termination of
any claim, issue or matter in any such Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. 

Section 7. Indemnification for Expenses of a Witness. 

Notwithstanding any other provision of the Agreement, to the extent that Indemnitee is, by reason of Indemnitee’s employment or service as
an officer or director, a witness in any Proceeding, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection therewith. 

Section 8. Advancement of Expenses. 

The Corporation shall advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding within thirty
(30) days after the receipt by the Corporation of a statement or statement from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall
reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by an undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not
entitled to be indemnified against such Expenses. 

  
 -B 3- 

 Section 9. Procedure for Determination of Entitlement to Indemnification. 

(a) To obtain indemnification under the Agreement in connection with any Proceeding, and for the duration thereof, Indemnitee shall submit to
the Corporation a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to
indemnification. The Secretary of the Corporation shall, promptly upon receipt of any such request for indemnification, advise the board in writing that Indemnitee has requested indemnification. 

(b) Upon written request by Indemnitee for indemnification pursuant to Section 9(a) hereof, a determination, if required by applicable
law, with respect to Indemnitee’s entitlement thereto shall be made in such case: (i) if a Change in Control shall have occurred, by Independent Counsel (unless Indemnitee shall request that such determination be made by the Board or the
stockholders in the manner provided for in clauses (ii) or (iii) or this Section 9(b)) in written opinion to the Board, a copy of which shall be delivered to Indemnitee; (ii) if a Change of Control shall not have occurred,
(A) by the Board by a majority vote of a quorum consisting of Disinterested Directors, or (B) if a quorum of the Board consisting of Disinterested Directors is not obtainable, or even if such quorum is obtainable, if such quorum of
Disinterested Directors so directs, either (x) by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, or (y) by the stockholders of the Corporation, as determined by such quorum of
Disinterested Directors, or a quorum of the Board, as the case may be; or (iii) as provided in Section 1O(b) of the Agreement. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made
within thirty (30) days after such determination. Indemnitee shall cooperate with the persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such persons or entity
upon request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including
attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the persons or entity making such determination shall be home by the Corporation (irrespective of the determination as to Indemnitee’s entitlement to
indemnification) and the Corporation hereby indemnifies and agrees to hold Indemnitee harmless therefrom. 
 (c) If required, Independent
Counsel shall be selected as follows: (i) if a Change of Control shall not have occurred, Independent Counsel shall be selected by the Board by a majority vote of a quorum consisting of Disinterested Directors and the Corporation shall give
written notice to Indemnitee advising Indemnitee of the identity of Independent Counsel so selected; or (ii) if a Change of Control shall have occurred, Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that
such selection be made by the Board, in which event (i) shall apply), and Indemnitee shall give written notice to the Corporation advising it of the identity of Independent Counsel so selected. In either event, Indemnitee or the Corporation, as
the case may be, may, within seven (7) days after such written notice of selection shall have been given, deliver to the Corporation or to Indemnitee, as the case may be, a written objection to such selection. Such objection may be asserted
only on the ground that Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 1 of the Agreement, and the objection shall set forth with particularity the factual basis of such
assertion. If such written objection is made, Independent Counsel so selected may not serve as Independent Counsel unless and until a court has determined that such objection is without merit. If, within twenty (20) days after submission by
Indemnitee of a written request for indemnification pursuant to Section 9(a) hereof, no Independent Counsel shall have been selected and not objected to, either the Corporation or Indemnitee may petition the Court of Chancery of the State of
Delaware, or any court in the Commonwealth of Massachusetts in which such petition would be cognizable, for resolution of any objection which shall have been made by the Corporation or Indemnitee to the other’s selection of Independent Counsel
and/or for the appointment as Independent Counsel of a person selected by such 

  
 -B 4- 

 
court or by such other person as such court shall designate, and the person with respect to whom an objection is so resolved or the person so appointed shall act as Independent Counsel under
Section 9(b) hereof. The Corporation shall pay any and all reasonable fees and expenses incurred by such Independent Counsel in connection with its actions pursuant to the Agreement, and the Corporation shall pay all reasonable fees and
expenses incident to the procedures of this Section 9(c) regardless of the manner in which such Independent Counsel was selected or appointed. Upon the due commencement date of any judicial proceeding pursuant to Section 11 (a)(iii) of the
Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). 

Section 10. Presumptions and Effects of Certain Proceedings. 

(a) If a Change in Control shall have occurred, in making a determination with respect to entitlement to indemnification hereunder, the person
or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under the Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 9(a) of the Agreement, and the
Corporation shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. 

(b) The person or entity empowered or selected under Section 9 of the Agreement shall make the determination of whether Indemnitee is
entitled to indemnification as soon as practicable after receipt by the Corporation of the request therefore. 
 (c) The termination of any
Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in the Agreement) of itself adversely affect
the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation or, with respect to
any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee’s conduct was unlawful. 
 Section 11. Remedies of
indemnitee. 
 (a) In the event that (i) a determination is made pursuant to Section 9 or 10 of the Agreement that Indemnitee
is not entitled to indemnification under the Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 8 of the Agreement, (iii) the determination of entitlement to indemnification is made by Independent Counsel
pursuant to Section 9 of the Agreement and such determination shall not have been made and delivered in a written opinion within ninety (90) days after receipt by the Corporation of the request for indemnification, or (iv) payment of
indemnification is not made within thirty (30) days after such determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to Sections 9 or 10 of the Agreement,
Indemnitee shall be entitled to an adjudication in an appropriate court of the State of Delaware or the Commonwealth of Massachusetts, of Indemnitee’s entitlement to such indemnification or advancement of Expenses. Indemnitee shall commence
such proceeding seeking an adjudication or an award within one hundred eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 11(a). 

(b) In the event that a determination shall have been made pursuant to Section 9 of the Agreement that Indemnitee is not entitled to
indemnification, any judicial proceeding commenced pursuant to the Section shall be conducted in all respects as a de novo trial and Indemnitee shall not be prejudiced by any reason of that adverse determination. If a Change of Control shall have
occurred, in any judicial proceeding commenced pursuant to the Section the Corporation shall have the burden of proving that Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be. 

  
 -B 5- 

 (c) If a determination shall have been made or deemed to have been made pursuant to
Section 9 or 10 of the Agreement that Indemnitee is entitled to indemnification, the Corporation shall be bound by such determination in any judicial proceeding commenced pursuant to the Section, absent (i) a misstatement by Indemnitee or
Indemnitee’s representative of a material fact, or an omission of any material fact necessary to make Indemnitee’s or Indemnitee’s representative’s statement not materially misleading, in connection with the request for
indemnification, or (ii) prohibition of such indemnification under applicable law. 
 (d) The Corporation shall be precluded from
asserting in any judicial proceeding commenced pursuant to the Section that the procedures and presumptions of the Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Corporation is bound by all the
provisions of the Agreement. 
 (e) In the event that Indemnitee, pursuant to the Section, seeks a judicial adjudication of
Indemnitee’s rights under, or to recover damages for breach of, the Agreement, Indemnitee shall be entitled to recover from the Corporation and shall be indemnified by the Corporation against, any and all expenses (of the kinds described in the
definition of Expenses) actually and reasonably incurred by Indemnitee in such judicial adjudication, but only if Indemnitee prevails therein. If it shall be determined that Indemnitee is entitled to receive part but not all of the indemnification
or advancement of expenses sought, the expenses incurred by Indemnitee in connection with such judicial adjudication shall be appropriately prorated. 

Section 12. Non-Exclusivity; Survival of Rights; Insurance Subrogation. 

(a) The rights of indemnification and to receive advancement of Expenses as provided by the Agreement shall not be deemed exclusive of any
other rights to which Indemnitee may at any time be entitled under applicable law, the certificate of incorporation or by-laws of the Corporation, any agreement, a vote of stockholders or resolution of directors or otherwise. No amendment,
alteration or repeal of the Agreement or any provision hereof shall be effective as to Indemnitee with respect to any action taken or omitted by such Indemnitee in Indemnitee’s employment or service as an officer or director prior to such
amendment, alteration or repeal. 
 (b) To the extent that the Corporation maintains an insurance policy or policies providing liability
insurance for directors, officers, employees, agents or fiduciaries of the Corporation or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person serves at the request of the
Corporation, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee, agent or fiduciary under such policy or policies.

 (c) In the event of any payment under the Agreement, the Corporation shall be subrogated to the extent of such payment to all of the
rights of recovery of Indemnitee who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Corporation to bring suit to enforce such rights. 

(d) The Corporation shall not be liable under the Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the
extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise. 

  
 -B 6- 

 Section 13. Duration of Agreement. 

The Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have
ceased to serve as a director, officer, employee, agent or fiduciary of the Corporation or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which Indemnitee served at the request of the
Corporation; (b) the final termination of all pending Proceedings in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 11
of the Agreement. The Agreement shall be binding upon the Corporation and its successors and assigns and shall inure to the benefit of Indemnitee and Indemnitee’s heirs. 

Section 14. Severability. 
 If any
provision or provisions of the Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of the Agreement (including, without limitation,
each portion of any Section of the Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal unenforceable) shall not in any way be affected or impaired thereby; and (b) to the
fullest extent possible, the provisions of the Agreement (including, without limitation, each portion of any Section of the Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or
unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable. 

Section 15. Exception to Right of Indemnification or Advancement of Expenses. 

Except as provided in Section 11(e), Indemnitee shall not be entitled to indemnification or advancement of Expenses under the Agreement
with respect to any Proceeding, or any claim therein, brought or made by Indemnitee against the Corporation. For the purposes of the Section 15, a Proceeding in the right of the Corporation shall not be deemed to constitute a Proceeding brought
or made by the Corporation. 
 Section 16. Identical Counterparts. 

The Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which
together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of the Agreement. 

Section 17. Headings. 
 The headings
of the paragraphs of the Agreement are inserted for convenience only and shall not be deemed to constitute part of the Agreement or to affect the construction thereof. 

Section 18. Modification and Waiver. 

No supplement, modification or amendment to the Agreement shall be binding unless executed in writing by both of the patties hereto. No waiver
of any of the provisions of the Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 

  
 -B 7- 

 Section 19. Notice by Indemnitee. 

Indemnitee agrees promptly to notify the Corporation in writing upon being served with any summons, citation, subpoena, complaint, indictment,
information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. 

Signed on December 19, 2016 in Boston, MA 

I, Alicia Secor, Chief Executive Officer, certify that the Board of Directors has authorized the Corporation to enter into the Agreement by a
resolution adopted at a meeting of the Board of Directors. 
 Signed on December 19, 2016 in Boston, MA 

  
 -B 8-EX-10.2

 Exhibit 10.2 

JUNIPER PHARMACEUTICALS, INC. 

INDUCEMENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT 

THIS AGREEMENT (the “Agreement”) is made effective as of the
            day of January, 2017 (hereinafter called the “Date of Grant”), between Juniper Pharmaceuticals, Inc., a Delaware corporation (hereinafter called the
“Company”), and Jeffrey Young (hereinafter called the “Participant”), as a material inducement to Participant becoming a senior executive of the Company. 

1. Non-Plan Grant; Incorporation of Terms of Plan. This nonqualified stock option (the “Option”) is made and granted
as a stand-alone award, separate and apart from, and outside of, the Juniper Pharmaceuticals, Inc. 2015 Long-Term Incentive Plan, as amended from time to time (the “Plan”), and shall not constitute an award granted under or pursuant
to the Plan. Notwithstanding the foregoing, the terms, conditions and definitions set forth in the Plan shall apply to the Option as though the Option had been granted under the Plan (including but not limited to the adjustment provision contained
in Section 14 of the Plan), and the Option shall be subject to such terms, conditions and definitions, which are hereby incorporated into this Agreement by reference. For the avoidance of doubt, the Option shall not be counted for purposes of
calculating Share Pool set forth in Section 5(a) of the Plan or for purposes of calculating the per Participant award limit per calendar year under Section 5(a) of the Plan. In the event of any inconsistency between the Plan and this
Agreement, the terms of this Agreement shall control. Notwithstanding any other provision of this Agreement to the contrary, the Option is granted either by a majority of the Company’s independent directors or by the independent compensation
committee of the Company’s board of directors within the meaning of NASDAQ Listing Rule 5605(a)(2). 
 2. Employment Inducement
Grant. The Option is intended to constitute an “employment inducement grant” under NASDAQ Listing Rule 5635(c)(4), and consequently is intended to be exempt from the NASDAQ rules regarding stockholder approval of stock option and stock
purchase plans. This Agreement and the terms and conditions of the Option shall be interpreted in accordance with and consistent with such exemption. 

3. Grant of the Option. In consideration of the mutual covenants hereinafter set forth, the Company hereby grants to the Participant
the Option to purchase, on the terms and conditions hereinafter set forth, all or any part of an aggregate of 170,000 Shares, subject to adjustment as set forth in the Plan. The exercise price of the Shares subject to the Option shall be
$[            ] per Share (the “Option Price”). The Option is intended to be a non-qualified stock option, and is not intended to qualify as an “incentive stock
option” as defined in Section 422 of the Internal Revenue Code of 1986, as amended. 
 4. Vesting. 

(a) The Option shall vest and become exercisable in accordance with the following schedule, if the Participant is employed by, or providing
service to, the Company on such date: 
  

					
	 First Anniversary of the Date of Grant
	  	 	25	% 
	 Second Anniversary of the Date of Grant
	  	 	25	% 
	 Third Anniversary of the Date of Grant
	  	 	25	% 
	 Fourth Anniversary of the Date of Grant
	  	 	25	% 

 5. Exercise of Option. 

 (a) Period of Exercise. The Option shall have a term of seven years from the Date of Grant
(the “Expiration Date”)and shall terminate at the expiration of that period, unless it is terminated at an earlier date pursuant to the provisions of this Agreement or the Plan. The Option shall automatically terminate upon the
happening of the first of the following events: 
  

	 	(i)	one year following the date of the Participant’s Termination of Service due to death or Disability; 

  

	 	(ii)	three months following the date of the Participant’s Termination of Service with the Company without Cause; and 

  

	 	(iii)	the date of the Participant’s Termination of Service with the Company for Cause or by the Participant for any reason other than due to the Participant’s death or Disability. 

Notwithstanding the foregoing or any other provision of the Plan of this Agreement to the contrary, no portion of this Stock Option shall be
exercisable after the Expiration Date. Any portion of the Option that is not exercisable at the time of the Participant’s Termination of Service shall immediately terminate. 

(b) Method of Exercise. 

(i) Subject to Section 6(c) of the Plan, the vested portion of the Option may be exercised by delivering to the Company at
its principal office written notice of intent to so exercise; provided that, the Option may be exercised with respect to whole Shares only. Such notice shall specify the number of Shares for which the Option is being exercised and shall be
accompanied by payment in full of the Option Price. The payment of the Option Price may be made at the election of the Participant (i) in cash, (ii) by the delivery of Shares then owned by the Participant, (iii) in the discretion of
the Committee, by directing the Company to withhold Shares otherwise deliverable upon exercise to satisfy the exercise price, (iv) by delivering a properly executed exercise notice to the Company together with a copy of irrevocable instructions
to a broker to deliver promptly to the Company in the amount of sale or loan proceeds to pay the exercise price as long as such transaction does not constitute an impermissible loan to an executive officer under Section 13(k) of the Exchange
Act (Section 402 of the Sarbanes-Oxley Act of 2002), or (v) by any other method the Committee may prescribe that it determines to be consistent with applicable law and the purpose of the Plan, including, without limitation, in lieu of the
exercise of an Option by delivery of Shares then owned by a Participant, providing the Company with a notarized statement attesting to the number of Shares owned, where upon verification by the Company, the Company would issue to the Participant
only the number of incremental Shares to which the Participant is entitled upon exercise of the Option. No Participant shall have any rights to dividends or other rights of a stockholder with respect to Shares subject to an Option until the
Participant has given written notice of exercise of the Option, paid in full for such Shares and, if applicable, has satisfied any other conditions imposed by the Committee pursuant to the Plan. 

(ii) Notwithstanding any other provision of the Plan or this Agreement to the contrary, the Option may not be exercised prior
to the completion of any registration or qualification of the Option or the Shares under applicable state and federal securities or other laws, or under any ruling or regulation of any governmental body or national securities exchange that the
Committee shall in its sole discretion determine to be necessary or advisable. 
 (iii) Upon the Company’s determination
that the Option has been validly exercised as to any of the Shares, the Company shall issue certificates in the Participant’s name for such Shares. However, the Company shall not be liable to the Participant for damages relating to any delays
in issuing the certificates to him, any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in the certificates themselves. 

  
 - 2 - 

 (iv) In the event of the Participant’s death, the vested portion of the
Option shall remain exercisable by the Participant’s executor or administrator, or the person or persons to whom the Participant’s rights under this Agreement shall pass by will or by the laws of descent and distribution as the case may
be, to the extent set forth in Section 5(a). Any heir or legatee of the Participant shall take rights herein granted subject to the terms and conditions hereof. 

6. Withholding. Prior to the issuance of shares upon the exercise of the Option, the Participant must make arrangements satisfactory to
the Company to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Committee, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to
satisfy such tax withholding obligation, in whole or in part by (without limitation) (i) electing to have the Company withhold Shares of Common Stock having a Fair Market Value equal to the amount of tax to be withheld or (ii) the delivery
of irrevocable instructions to a broker to deliver promptly to the Company an amount equal to the amount required to be withheld. However in no event will the amount of Shares withheld exceed the amount necessary to satisfy the required minimum
statutory withholding. 
 7. Change of Control. Upon a Change of Control (as defined by the Plan), the terms of the Plan shall apply
as if this Option was an Award made under the Plan. 
 8. Option Recovery. If the Committee determines that the Participant
(a) engaged in conduct that constituted Cause (as defined in the Plan) at any time prior to the Participant’s Termination of Service, (b) engaged in conduct during the one year period after the Participant’s Termination of
Service that would have constituted Cause if the Participant had not ceased to provide services, or (c) violates the terms of any non-compete agreement, non-solicitation agreement, confidentiality agreement, or any other restriction on the
Participant’s post-termination activities established under any agreement with the Company or other Company policy or arrangement during the one year after the Participant’s Termination of Service, then (i) any Option held by the
Participant shall immediately terminate without consideration and (ii) the Participant shall return any Shares received upon exercise of the Option or repay to the Company any proceeds received from the sale of other disposition of the Shares
transferred pursuant to the Option less the Exercise Price. Upon any exercise of an Option, the Company may withhold delivery of share certificates pending resolution of an inquiry that could lead to a finding resulting in a forfeiture under this
Section. 
 9. Legend on Certificates. The certificates representing the Shares purchased by exercise of the Option shall be subject
to the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which such Shares are listed, and any applicable federal or state laws, and the Committee may cause a legend or legends to be put on
any such certificates to make appropriate reference to such restrictions. 
 10. Transferability. The Option may not be assigned,
alienated, pledged, attached, sold or otherwise transferred or encumbered by the Participant otherwise than by will or by the laws of descent and distribution, and any such purported assignment, alienation, pledge, attachment, sale, transfer or
encumbrance shall be void and unenforceable against the Company or any affiliate; provided that the designation of a beneficiary shall not constitute an assignment, alienation, pledge, attachment, sale, transfer or encumbrance. No such permitted
transfer of the Option to heirs or legatees of the Participant shall be effective to bind the Company unless the Committee shall have been furnished with written notice thereof and a copy of such evidence as the Committee may deem necessary to
establish the validity 

  
 - 3 - 

 
of the transfer and the acceptance by the transferee or transferees of the terms and conditions hereof. During the Participant’s lifetime, the Option is exercisable only by the Participant,
and shall not be transferable otherwise than by will or the laws of descent and distribution. 
 11. Securities Laws. Upon the
acquisition of any Shares pursuant to the exercise of the Option, the Participant will make or enter into such written representations, warranties and agreements as the Committee may reasonably request in order to comply with applicable securities
laws or with this Agreement. 
 12. No Right to Continued Employment. Neither the Plan nor this Agreement shall confer upon the
Participant any right to be retained in any position, as an Employee, Director or consultant of the Company. Further, nothing in the Plan or this Agreement shall be construed to limit the discretion of the Company to terminate the Participant at any
time, with or without Cause. 
 13. No Impact on Other Benefits. The value of the Participant’s Option is not part of his or her
normal or expected compensation for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit. 

14. Notices. Any notice necessary under this Agreement shall be addressed to the Company in care of its Secretary at the principal
executive office of the Company and to the Participant at the address appearing in the personnel records of the Company for the Participant or to either party at such other address as either party hereto may hereafter designate in writing to the
other. Any such notice shall be deemed effective upon receipt thereof by the addressee. 
 15. Choice of Law. This Agreement shall be
governed by and construed in accordance with the laws of the state of Delaware without regard to conflicts of laws. 
 16. Broad
Authority. By accepting this Agreement, the Participant agrees and acknowledges that all decisions and determinations of the Committee shall be final and binding on the Participant, his or her beneficiaries and any other person having or
claiming an interest in the Option. 
 17. Signature in Counterparts. This Agreement may be signed in counterparts, each of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 
 18.
Severability. If any provision of this Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or would disqualify this Agreement or the Option under any applicable law, such provision shall be
construed or deemed amended to conform to applicable law (or if such provision cannot be so construed or deemed amended without materially altering the purpose or intent of this Agreement and the grant of the Option hereunder, such provision shall
be stricken as to such jurisdiction and the remainder of this Agreement and the award shall remain in full force and effect). 
 19.
Complete Agreement. Except as otherwise provided for herein, this Agreement and those agreements and documents expressly referred to herein embody the complete agreement and understanding among the parties and supersede and preempt any prior
understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way. The terms of this Agreement shall be binding upon the executors, administrators, heirs,
successors and assigns of the Participant. 
 [Signatures on next page.] 

  
 - 4 - 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be effective as of the day and year
first above written. 
  

	
	Juniper Pharmaceuticals, Inc.
	
	   

	Name:
	
	   

	Title:
	
	   

  

	
	Participant
	
	   

	Name: Jeffrey Young

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]